Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours

NCT06238336 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hematological Malignancy

Interventions

DRUG: CAR-T cell therapy

Sponsor

Shanxi Bethune Hospital